menu
    • menu
    [{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Columbia University | Drexel University College of Medicine | Rutgers, The State University of New Jersey | Lehigh Valley Hospital | Saint Peter\u2019s University Hospital | Christiana Care Health Services | Washington University School of Medicine | Duke Univ","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Labetalol Hydrochloride","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Columbia University | Drexel University College of Medicine | Rutgers, The State University of New Jersey | Lehigh Valley Hospital | Saint Peter\u2019s University Hospital | Christiana Care Health Services | Washington University School of Medicine | Duke Univ","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Columbia University | Drexel University College of Medicine | Rutgers, The State University of New Jersey | Lehigh Valley Hospital | Saint Peter\u2019s University Hospital | Christiana Care Health Services | Washington University School of Medicine | Duke Univ"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Labetalol Hydrochloride","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Labetalol Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Caplin Steriles","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caplin Steriles \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Caplin Steriles \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"ProvideGx","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Labetalol Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ ProvideGx","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ ProvideGx"}]

    Find Clinical Drug Pipeline Developments & Deals for Labetalol HCl

    Menu

    Labetalol HCl

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Caplin Steriles

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Caplin Steriles

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Labetalol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Caplin Steriles Gets USFDA Nod for Labetalol Hydrochloride Injection

                            Details : U.S FDA has given Abbreviated New Drug Application labetalol hydrochloride injection USP, 100 mg/20 mL (5 mg/mL) and 200mg/40 mL (5 mg/mL) multiple-dose vials, a generic therapeutic equivalent version of Trandate injection, of Sebela Ireland Limited.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 09, 2021

                            Lead Product(s) : Labetalol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pfizer Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Labetalol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : ProvideGx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ProvideGx® Partners with Pfizer Inc. to Secure the Supply of Five Essential Medications

                            Details : The five medicines include: diazepam, labetalol, lorazepam, fentanyl citrate and 0.9% sodium chloride injection. Deal aims support to healthcare providers, helping to meet the immediate and long-term supply needs of drugs necessary to a range of patient ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 21, 2021

                            Lead Product(s) : Labetalol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : ProvideGx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hamilton Health Sciences

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hamilton Health Sciences

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Labetalol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Blood Pressure Management in Stroke Following Endovascular Treatment

                            Details : Labetalol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 23, 2020

                            Lead Product(s) : Labetalol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of Alabama at Birmingham

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Alabama at Birmingham

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Labetalol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Columbia University | Drexel University College of Medicine | Rutgers, The State University of New Jersey | Lehigh Valley Hospital | Saint Peter’s University Hospital | Christiana Care Health Services | Washington University School of Medicine | Duke Univ

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chronic Hypertension and Pregnancy (CHAP) Project

                            Details : Labetalol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 24, 2014

                            Lead Product(s) : Labetalol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Columbia University | Drexel University College of Medicine | Rutgers, The State University of New Jersey | Lehigh Valley Hospital | Saint Peter’s University Hospital | Christiana Care Health Services | Washington University School of Medicine | Duke Univ

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth